Anavex Life Sciences Stock Rises After Experimental Alzheimer's Drug Slows Cognitive Decline In Study
(MENAFN- AsiaNet News)
Anavex Life Sciences Corp. (AVXL) on Tuesday announced that its experimental Alzheimer's drug demonstrated cognitive stabilization in patients with early Alzheimer's disease.
After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine demonstrated barely detectable cognitive decline, comparable to the minimal decline in pre-dementia ageing adults.
Shares of the company rose 4% in the pre-market session.
Get updates to this developing story <directly on Stocktwits.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Bitcoin Adoption On Sui Accelerates As Threshold Network And Sui Launch Phase 2 Of Tbtc Integration
- Meme Coin Little Pepe Raises Above $24M In Presale With Over 39,000 Holders
- Schoenherr Welcomes Top-Tier CEE English Law Debt Finance Team
- Japan Buy Now Pay Later Market Size To Surpass USD 145.5 Billion By 2033 CAGR Of 22.23%
- United States Insulin Pumps Market Forecast On Share & Demand Mapping 20252033
- Mediafuse Joins Google For Startups Cloud Program To Scale AI-Driven, Industry-Focused PR Distribution
More Story
Comments
No comment